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ABSTRACT
Introduction Hormone replacement therapy (HRT) can help 
women experiencing menopausal symptoms, but usage has 
declined due to uncertainty around risks of cancer and some 
cardiovascular diseases (CVD). Moreover, improved cancer 
survival rates mean that more women who survive cancer 
go on to experience menopausal symptoms. Understanding 
these relationships is important so that women and their 
clinicians can make informed decisions around the risks and 
benefits of HRT. This study’s primary aim is to determine the 
association between HRT use after cancer diagnosis and the 
risk of cancer- specific mortality. The secondary aims are to 
investigate the risks of HRT on subsequent cancer, all- cause 
mortality and CVD.
Methods and analysis We will conduct a population- based 
longitudinal cohort study of 18–79 year- old women diagnosed 
with cancer between 1998 and 2020, using the QResearch 
database. The main exposure is HRT use, categorised based 
on compound, dose and route of administration, and modelled 
as a time- varying covariate. Analysis of HRT use precancer 
and postcancer diagnosis will be conducted separately. The 
primary outcome is cancer- specific mortality, which will 
be stratified by cancer site. Secondary outcomes include 
subsequent cancer diagnosis, CVD (including venous thrombo- 
embolism) and all- cause mortality. Adjustment will be made 
for key confounders such as age, body mass index, ethnicity, 
deprivation index, comorbidities, and cancer grade, stage and 
treatment. Statistical analysis will include descriptive statistics 
and Cox proportional hazards models to calculate HRs and 
95% CIs.
Ethics and dissemination Ethical approval for this 
project was obtained from the QResearch Scientific 
Committee (Ref: OX24, project title ‘Use of hormone 
replacement therapy and survival from cancer’). This 
project has been, and will continue to be, supported by 
patient and public involvement panels. We intend to the 
submit the findings for peer- reviewed publication in an 
academic journal and disseminate them to the public 
through Cancer Research UK.
BACKGROUND
Prevalence of HRT use
Hormone replacement therapy (HRT) 
involves clinical provision of the female 
sex hormone oestrogen either on its own 
or in combination with another hormone, 
progestogen. It is an effective and important 
treatment for symptoms of the menopause, 
including vasomotor symptoms (hot flushes 
and night sweats), urogenital atrophy1 and 
postmenopausal osteoporosis.2 Yet between 
2002 and 2005, HRT usage in the UK dropped 
from approximately 29% of postmeno-
pausal women to approximately 11%,3 and 
this pattern was consistent across Europe.4 
The drop in usage has been attributed to 
the widely reported findings of the Million 
Women’s Study5 and the early cessation of 
the Women’s Health Initiative trial,3 4 6 which 
concluded that an observed increase in risk 
of cardiovascular events and breast cancer 
in women taking combined oestrogen and 
progestogen HRT outweighed the benefits 
of reduced rates of colorectal cancer and 
osteoporotic fractures.7 Evidence from a 
recent Cochrane systematic review and meta- 
analysis though, suggests that HRT remains 
an important treatment option for women 
with severe menopausal symptoms who do 
not have other risk factors, such as oestrogen 
sensitive cancers.8 Given the demonstrated 
risks and benefits of HRT, there is a need to 
Strengths and limitations of this study
 ► This is an open cohort study comprising a nationally 
representative sample of English women.
 ► The cohort consists of General Practice (GP) clinic 
data linked to hospital records, the English national 
cancer registry and English national death registry.
 ► This study has access to detailed information on 
hormone replacement therapy prescriptions, allow-
ing analysis with consideration of the specific com-
pound, dose, route of administration and duration of 
exposure.
 ► This study is limited by high rates of missing data for 
cancer grade and stage, although completeness has 
improved in recent years, this will be accounted for 
using appropriate multiple imputation techniques.
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clarify which women can use it safely, to treat menopausal 
symptoms without unduly increasing their risk of adverse 
outcomes.
HRT in women with cancer
The role of oestrogen in cancer is complex, with evidence 
that it accelerates cancer progression in some sites but 
slows it in others. For instance, preclinical studies have 
shown that oestrogen stimulates growth in bladder9 and 
gastric cancer cell lines10 but, in contrast, similar studies 
found that it inhibits cell growth and/or induces apop-
tosis in oesophageal adenocarcinoma11 and malignant 
melanoma cell lines.12 What’s more, in a mouse model 
oestrogen increased the number and volume of lung 
adenocarcinomas,13 and molecular pathological studies 
have shown oestrogen receptor expression is associated 
with metastasis and poorer survival in gastric cancer.14 
Epidemiological studies also report contrasting findings 
depending the cancer of interest, with some showing 
markedly lower incidence and slightly better survival 
for women compared with men for many cancers,15 16 
whereas another study demonstrated survival after gastric 
cancer is worse in young women (<45 years old) than 
in young men, but similar in older women and men.17 
The complex relationship between oestrogen and cancer 
raises questions as to how HRT can be safely provided for 
women experiencing menopausal symptoms.
Similar to investigations of oestrogen’s role in various 
cancers, findings from studies of HRT and cancer risk are 
mixed. For example, HRT use is associated with a reduced 
risk of liver,18–20 oesophageal20 and colorectal cancers20–23 
but an increased risk of glioma and meningioma with 
use of oestrogen only HRT.24 In some cases evidence is 
conflicting for individual cancers, for example, a recent 
meta- analysis of lung cancer found a reduced risk in 
women taking HRT25 but an earlier meta- analysis found 
no effect;26 and in non- Hodgkin’s lymphoma, for which a 
pooled analysis of case- control studies showed decreased 
incidence in women using HRT,27 but two cohort studies 
found no effect.28 29 Furthermore, a cohort study found 
bladder cancer to be less common in women using 
combined, but not oestrogen- only HRT,30 suggesting that 
the specific HRT prescription affects its association with 
cancer.
There are also important questions relating to the risk 
of HRT use by women who have survived or are living 
with cancer. This is increasingly important for several 
reasons: first, improved survival rates from cancer mean 
female survivors are increasingly likely to experience 
menopause;31 second, in young women with cancer, the 
associated treatment may cause primary ovarian insuf-
ficiency,31 32 inducing menopause and thus potentially 
indicating HRT in this demographic; and third, the 
induction of ‘surgical’ menopause by hysterectomy and 
oophorectomy could be an indication for HRT.33 While a 
number of studies have found protective effects of HRT 
after colorectal cancer,34–36 epidemiological evidence at 
other cancer sites is sparse. For instance, HRT use after 
cancer diagnosis was associated with reduced mortality 
in 205 patients with melanoma,37 but this was based 
on only one cancer- specific death in HRT users. Simi-
larly, HRT before diagnosis was associated with reduced 
mortality in 234 patients with primary liver cancer, but 
HRT after diagnosis was not investigated.19 A case control 
study of patients with Hodgkin’s lymphoma with and 
without subsequent breast cancer did not find that risk 
was increased by HRT.38 Finally, in a study of 130 patients 
with leukaemia no excess recurrences were observed in 
HRT users.39 Further investigation into the potential asso-
ciation between HRT and cancer survival is warranted 
because existing evidence comes from small studies with 
limited power, many of which did not investigate HRT 
after diagnosis, and many cancer sites have not been 
investigated at all.
Despite the lack of high quality epidemiological 
evidence, there have been suggestions that HRT should 
be used cautiously, or not at all, in patients with lung,31 40 
bladder,31 41 gastric31 41 and brain cancer.31 41 These recom-
mendations may be concerning for patients, and for clini-
cians there is limited information on providing HRT in 
women with cancers other than breast cancer in clinical 
guidelines.42 43 This can lead to avoidance of HRT in line 
with the ‘precautionary principle’, but such an approach 
has been severely criticised because of the clear benefits of 
HRT in reducing menopausal symptoms and increasing 
health- related quality of life.31 44 There is a need to clarify 
the relationship between HRT and non- oestrogen depen-
dent cancers so that women of all ages who survive cancer 
can make informed choices with their treating clinicians 
as to the risks and benefits of HRT.
Risk of cardiovascular disease and venous thromboembolism 
associated with HRT
In addition to cancer, there are concerns that HRT may 
lead to cardiovascular complications. A recent Cochrane 
systematic review with meta- analysis of 22 largely high 
quality studies found moderate evidence that combined, 
continuous HRT is associated with an increased risk of 
myocardial infarction (MI), stroke and venous thrombo-
embolism (VTE), and that oestrogen only, continuous 
HRT is associated with stroke and VTE but not MI.8 The 
authors concluded that while the absolute risk of these 
outcomes remained low, the clear association meant that 
the increased relative risk is a relevant consideration 
for all women and may contraindicate HRT in those at 
increased risk of cardiovascular disease (CVD). A more 
recent systematic review of 33 observational studies, 
however, had contradictory findings that HRT may 
protect against CVD, and that the duration, dose, timing 
and means of HRT administration affected the relation-
ship.45 Importantly, the authors noted inconsistent results 
in the included studies and a wide range in their overall 
scientific quality. The higher quality of studies included 
in the Cochrane review lend greater weight to its find-
ings, but the more recent systematic review indicates that 
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further research into the specific type and administration 
of HRT in high quality studies is needed.
Summary
There are legitimate concerns about the safety of 
prescribing HRT for women with cancer and those at 
elevated risk of VTE or CVD. The role of HRT in improving 
the quality of life for women during menopause, however, 
means that understanding how and for whom it can be 
safely prescribed is essential. Furthermore, the increasing 
number of women who survive cancer and go on to expe-
rience menopausal symptoms suggests that investigation 
is warranted into this demographic specifically.
Aims and objectives
Our primary aim is to determine the association between 
HRT use and the risk of cancer- specific mortality in women 
with a range of common cancers. Our secondary aim is to 
quantify the risks of HRT associated with subsequent cancer, 
all- cause mortality, CVD and VTE in women with cancer. Our 
study will provide patients with cancer and clinicians with 
the high quality evidence of the safety of HRT in patients 
with cancer, allowing them to make informed decisions, and 
will provide important mechanistic insights into the role of 
oestrogen in cancer progression.
METHODS AND ANALYSIS
Study design and data source
A population- based cohort study will be conducted using 
the QResearch linked database. QResearch is a large, vali-
dated database of anonymised electronic health records 
and is representative of the English general population.46 It 
compiles patient data at an individual level from GP practices 
through the Egton Medical Information Systems electronic 
health records and has linkages to National Health Service 
(NHS) data through the NHS Digital Hospital Episode Statis-
tics (HES) platform, the English national cancer registry and 
the English national death register, and has been described 
in detail previously.47
Study sample
We will identify an open cohort of women aged 18–79 
years who have been registered at a GP clinic contributing 
data to QResearch for at least 1 year prior to diagnosis 
of one of the included types of cancer (table 1). Women 
with cancer will be identified from the English national 
cancer registry and this will be supplemented with GP 
clinic records and HES data. The study period is between 
1998 and the most recent available data, with censoring at 
either the date of death or the end of the study period in 
the primary analysis, and at development of subsequent 
cancer, CVD or VTE in the relevant secondary analyses. 
Exclusion criteria are: women with a previous diagnosis of 
invasive cancer (other than those listed) or who have less 
than 1 year of follow- up available in the database. Breast 
cancer will not be included since HRT is contraindicated 
in breast cancer and oestrogen dependent tumours.2 42 48
Exposure
We will extract data on HRT prescriptions from the 
QResearch database. Treatment will be categorised 
based on compound (type of oestrogen and type of 
progestogen where applicable), route of administration 
(oral, transdermal, vaginal, injection or implant), dose 
(≤0.625 mg for oral conjugated equine oestrogen, ≤1 mg 
for oral estradiol, ≤50 µg for transdermal estradiol,49 
timing (ie, relative to cancer diagnosis) and duration. 
Daily defined doses (DDDs) will be extrapolated from 
prescription information where possible; however, it may 
not be possible in some cases, such as administration by 
transdermal patch or gel.
Outcomes
Outcomes related to cancer mortality
The primary outcome is cancer specific mortality where 
cancer is recorded as the primary or underlying cause 
of death. This will be ascertained using the primary or 
underlying cause of death as recorded on the linked 
mortality data from the Office of National Statistics death 
register. Our secondary outcomes will be incident cases 
of cancer as recorded on either the GP, hospital, cancer 
registry or linked mortality record and all- cause mortality.
Outcomes related to CVD and VTE
A CVD event will be defined as the earliest record of CVD 
where it is the primary reason for admission on the GP or 
HES databases, or where it is recorded as primary cause of 
death on the mortality record. A CVD event will include 
coronary heart disease or stroke.
As for CVD, a VTE event will be defined as the earliest 
record of VTE on any of the three linked data sources 
(GP, HES or mortality record). VTE will include deep 
vein thrombosis or pulmonary embolism.
Confounding variables
Key demographic factors, potentially confounding factors 
and data relating to the secondary outcome (CVD) are 
listed below and will be obtained from GP records. Cate-
gories of confounders that may apply to both outcomes 
but with different specific inclusions (eg, pharmaco-
therapy) are listed in table 2, with specific inclusions 
shown separately for each outcome.
Table 1 Included cancer sites of primary tumours by 
classification
Category Specific tumour site
Haematological Leukaemia, multiple myeloma, non- 
Hodgkin’s lymphoma
Gastrointestinal Oral, oesophageal, gastric, liver, 
pancreatic, colorectal
Gynaecological Cervical, ovarian, endometrial
Urogenital Renal, bladder
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Demographic and lifestyle factors
 ► Year of birth.
 ► Age at cancer diagnosis.
 ► Townsend deprivation score.
 ► Most recent body mass index (BMI) prior to outcome 
diagnosis.
 ► Family history of cancer.
 ► Ethnicity (White, Indian, Bangladeshi, Pakistani, 
Chinese, other Asian, Caribbean, Black African, 
other).
 ► Most recent smoking status (never, former, light, 
moderate, heavy) prior to outcome diagnosis.
 ► Most recent alcohol consumption status (non- drinker, 
trivial, light, moderate, heavy, very heavy) prior to 
outcome diagnosis.
 ► Geographical region (East of England, East Midlands, 
West Midlands, London, North East, North West, 




 ► Stage: 1–4 as per Tumour Nodes Metastases classifica-
tion, or International Federation of Gynaecology and 
Table 2 Categories of confounders with specific inclusions for each outcome shown separately
Cancer- related analyses CVD and VTE- related analyses
Charlson Comorbidity Index 
(CCI) conditions
Cardiovascular diseases
 ► Coronary heart disease (myocardial 
infarction or angina)
 ► Congestive cardiac failure
 ► Peripheral vascular disease
 ► Stroke/ transient ischaemic attack
Gastrointestinal conditions
 ► Peptic ulcer disease
 ► Liver disease
 ► Inflammatory bowel disease
Other CCI conditions
 ► Dementia
 ► Chronic obstructive pulmonary 
disease
 ► Connective tissue disease
 ► Haemiplegia
 ► Moderate or severe chronic kidney 
disease
 ► Diabetes mellitus (type 1 or type 2)
 ► HIV/ AIDS
Gastrointestinal conditions
 ► Peptic ulcer disease
 ► Liver disease
 ► Inflammatory bowel disease
Other CCI conditions
 ► Dementia
 ► Chronic obstructive pulmonary disease
 ► Connective tissue disease
 ► Hemiplegia
 ► Moderate or severe chronic kidney disease
 ► Diabetes mellitus (type 1 or type 2)
 ► HIV/ AIDS
Other comorbidities  ► Severe mental illness
 ► Depression
 ► Venous thromboembolism
 ► Vertebrobasilar insufficiency 
syndrome
 ► Anaemia
 ► Severe mental illness
 ► Depression
 ► Anaemia






 ► Anticoagulant drugs—warfarin, oral and parenteral 
anticoagulants
 ► Antihypertensive drugs—Angiotensin Converting Enzyme 
(ACE)- inhibitors, beta- blockers, calcium channel blockers, 
diuretics
 ► Antiplatelet drugs—aspirin, clopidogrel, dipyridamole, 
prasugrel, ticagrelor, ticlopidine
 ► Mental health drugs
 – Antidepressants—tricyclic antidepressants, compound 
antidepressants, mono- amine oxidase inhibitors
 – Antipsychotic drugs
 ► Analgesic drugs
 – Non- steroidal anti- inflammatories
 – Opioids
 ► Drugs of cancer treatment—tamoxifen, aromatase inhibitors, 
thalidomide, lenalidomide, bevacizumab
 ► Immunosuppressant drugs
 ► Antidiabetes drugs—insulin, oral hypoglycaemics
 ► Prostaglandin analogues
 ► Other hormone therapies
 – Oral contraceptive drugs—dianette
 – Topical hormone drugs
 – Megestrol acetate
CVD, cardiovascular disease; HRT, hormone replacement therapy; VTE, venous thromboembolism.
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Obstetrics (FIGO) staging system for gynaecological 
cancers.
 ► Grade: well, moderately, poorly or not differentiated.
Cancer treatment within 6 months of diagnosis51
 ► Radiotherapy.
 ► Chemotherapy.
 ► Hormonal therapy for cancer as recorded on the 
cancer registry.
 ► Cancer- related surgery:
 – Lung—resection, for example, pneumonectomy or 
lobectomy.
 – Colorectal—haemicolectomy, colectomy, endo-
scopic resection.
 – Pancreatic—pancreaticoduodenectomy, distal 
pancreatectomy.
 – Gynaecological—hysterectomy with or without 
bilateral salpingo- oophorectomy, pelvic exentera-
tions, cone biopsy or Large Loop Excistion of the 
Transformation Zone (LLETZ).
 – G a s t r o -  o e s o p h a g e a l — o e s o p h a g e c t o m y, 
gastrectomy.
 – Oral—lip resection, excision of oral lesion, 
glossectomy, maxillectomy, mandibulectomy, 
laryngectomy.
 – Thyroid cancers—thyroidectomy with or without 
neck dissection.
 – Urogenital—nephrectomy, nephroureterectomy, 
cystectomy.
 – Liver cancers—segmental resection, lobectomy, 
transplantation.
 – Brain cancers—craniectomy with resection.
Other surgery (ie, not cancer related)
 ► Hysterectomy with or without oophorectomy.
Statistical analysis
Analysis of HRT use after cancer diagnosis
Patients will be followed from 6 months after cancer 
diagnosis to cancer- specific mortality (censored on death 
from other causes or end of follow- up). A delay such as 
this is recommended to exclude deaths related to severe 
pathology to which HRT use is unlikely to have contrib-
uted. The length of the delay will be varied for certain 
cancers (such as melanoma, non- Hodgkin’s lymphoma, 
bladder, colorectal and thyroid cancer) as they have 
better prognosis.
A dose–response analysis will be conducted based on 
DDD’s, and number and duration of prescriptions. To 
avoid immortal time bias, HRT use will be modelled as a 
time varying covariate, that is, patients will only be consid-
ered users after a lag of 6 months from their first HRT 
prescription. Therefore, individuals will be considered 
users of 0–1 year from 6 months after their first prescrip-
tion to 6 months after their 12th prescription (or 365th 
DDD) and >1 year users after this time (table 3A). Other 
elements of HRT prescription, namely dose, means of 
administration and whether administration is continuous 
or cyclical will be investigated through stratification of the 
sample.
Time- dependent Cox regression models will be used 
to calculate HRs, and 95% CIs, for HRT use after cancer 
diagnosis adjusting for potential confounders including: 
age at diagnosis, BMI, year of diagnosis, alcohol and 
smoking status, ethnicity, deprivation index, stage, grade, 
cancer treatment, comorbidities, routine medications 
and prior hysterectomy/oophorectomy.
Analysis of HRT use before cancer diagnosis
Patients will be followed from diagnosis to cancer- specific 
mortality. HRT use will be identified in the 18 months 
prior to diagnosis, excluding the 6 months immediately 
prior to diagnosis (table 3B). Exclusion of HRT use in this 
period is intended to avoid bias arising from potentially 
short- term prescriptions issued in the lead up to cancer 
diagnosis that are unlikely to affect the outcome and may 
result in misclassification.52 Cox regression models will 
be used to calculate HRs and 95% CIs for cancer- specific 
Table 3 A–C: Categorisation of hormone replacement therapy (HRT) users for each proposed analysis
Label Definition
3A. HRT use after cancer diagnosis
Non- user No HRT prescription, or <6 months from first HRT prescription
0–1 year user 6 months after first prescription until 6 months after 12th prescription or 6 months after 365th DDD
>1 year user Prescriptions beyond above time points
3B. HRT use before cancer diagnosis
Non- user No HRT prescription in the period from 18 months to 6 months before cancer diagnosis
User HRT prescription in the period from 18 months to 6 months before cancer diagnosis
3C. HRT use and CVD
Non- user A woman without an HRT prescription
Current user A woman with a valid HRT prescription
Past user A woman whose HRT prescription has expired and who does not renew the prescription within 30 days
CVD, cardiovascular disease; DDD, daily defined dose.
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death in HRT users compared with non- users. Adjusted 
Cox regression models will include: age at diagnosis, BMI, 
year of diagnosis, alcohol and smoking status, ethnicity, 
deprivation index, comorbidities, prior hysterectomy/
oophorectomy and routine medication use before diag-
nosis. Stage, grade and cancer treatments will initially 
be excluded from the models investigating HRT before 
diagnosis, as they could lie on the causal pathway. Subse-
quent analysis, however, will explore their potential role 
as confounders or effect mediators. Similar analyses will 
be conducted for secondary outcomes.
Confounding factors for specific cancer sites
Analyses will be stratified by cancer site, and some sites 
will be adjusted for additional covariates that have been 
shown to be associated with outcome at those sites. For 
instance, analysis of lung cancer will additionally contain 
histology (small- cell/non- small- cell) and beta- blocker use; 
colorectal will additionally contain site (colon, rectum or 
rectosigmoid colon), family history of colorectal cancer 
and inflammatory bowel disease; and oesophageal will 
contain histology (adenocarcinoma and squamous cell).
Analysis of CVD
In the secondary analysis of CVD, a start/stop time- varying 
covariate analysis will be conducted to investigate current 
HRT use, in which patients will become HRT users on the 
date of each HRT prescription, and remain HRT users 
until the end of their current prescription, at which point 
they will become past HRT users (table 3C) unless they 
initiate another HRT treatment within 30 days.
Cox regression models will be used to calculate HRs 
and 95% CIs for CVD events in HRT users and non- 
users. Adjustment will be made for: age at diagnosis, BMI, 
ethnicity, alcohol and smoking status, year of diagnosis, 
comorbidities and medications.
Meta-analysis
The HRs and SEs from these analyses will be pooled with 
identical analyses conducted on cohorts from Scotland 
and Wales. This two- stage analysis procedure will use 
random effects models to pool results across cohorts.
Sensitivity analyses
Confounding will primarily be addressed by entering a 
wide range of covariates into the Cox regression models. 
A number of additional sensitivity analyses will also be 
conducted to check for potential bias and subgroup 
effects including the following:
1. Analyses will be stratified into age categories of: 18 to 
<40, 40 to <55 and ≥55 years old. Women younger than 
40 are more likely to have experience premature ovar-
ian insufficiency whereas those 55 or over are likely to 
have experienced natural menopause.
2. An analysis of HRT after cancer diagnosis will be con-
ducted using a new- user design, that is, restricting 
analyses to patients with cancer who did not use HRT 
before diagnosis.
3. A negative control analysis will be conducted to check 
for unmeasured confounding by repeating the main 
analysis with death from other causes as the outcome 
because HRT is not expected to influence death from 
other causes (excluding cancer and CVD).
4. It is possible that poor compliance may confound the 
analyses. To investigate this an analysis excluding indi-
viduals with only one prescription will be conducted, 
as patients continuing to be prescribed HRT are more 
likely to be adhering to their prescriptions.
5. A propensity score matched analysis will be conduct-
ed. First, logistic regression will be used to determine 
the propensity to be prescribed HRT. Matching will be 
implemented in Stata (Statacorp LLC, Texas, USA) 
to identify a HRT user group and a propensity score 
matched non- user group. Cox regression will then be 
used to determine the time to cancer- specific death in 
the two groups.
Missing data
Multiple imputation will be used to impute missing values 
for variables including BMI, smoking and alcohol status, 
stage and grade according to published guidelines.53 As 
recommended, cancer- specific death status and cumula-
tive hazard will be included in imputation models as will 
all variables included in regression models. The number 
of imputed datasets will correspond to the proportion of 
missing data and results will be combined using Rubin’s 
rules.54
Limitations
The completeness of stage data will be of importance to 
the analysis of HRT after diagnosis. Stage completeness is 
expected to be high for the majority of cancers we propose 
investigating including lung cancer (~90%); colorectal 
cancer (~90%) and malignant melanoma (~80%).55 For 
other sites and earlier years of diagnosis, however, stage is 
more likely to be missing, so it will be imputed by multiple 
imputation where necessary. Stage completeness is not 
expected to unduly influence the analysis of HRT before 
cancer diagnosis on survival and is arguably not appro-
priate, as it could lie on the causal pathway in these cases.
Smoking and BMI are well recorded in GP records but 
are not complete. Completeness for smoking is estimated 
to be approximately 95% in recent UK GP records and 
for BMI it is roughly 80%. Multiple imputation will be 
used to impute missing values for these factors.
There are several potential sources of bias that arise 
from a likely difference in prescribing patterns of HRT 
for women with cancer. An allocation bias may arise 
because women with more severe cancer are less likely to 
be prescribed HRT and therefore more likely to be allo-
cated to the unexposed group. Alternatively, there may 
be a general aversion to prescribing HRT in this popu-
lation, so that only those women whose cancers have a 
high chance of remission are considered for HRT. We will 
seek to address this in several ways, first, these concerns 
would not affect prescription patterns prior to cancer 
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diagnosis, second, a ‘new- user’ sensitivity analysis will be 
conducted which excludes individuals with a history of 
HRT use prior to their cancer diagnosis. These analyses 
will provide a basis for assessing the potential impact of 
differing prescribing patterns and allocation bias.
Sample size calculation
Detectable HRs were calculated based on case numbers 
from the English study cohort (table 4). Statistical power 
to detect a difference (the beta value) was set at 90% and 
significance (the alpha value) at 5%. We estimated that 
7% of female patients with cancer would use HRT after 
diagnosis, consistent with published reports of roughly 
5% HRT usage in a Swedish population- based colorectal 
cancer cohort after diagnosis,34 and 9% HRT usage in a 
Danish melanoma cohort after diagnosis.56 These calcula-
tions show that we would be able to detect HRs of 1.5 or 
greater with HRT use after diagnosis for most cancer sites.
ETHICS AND DISSEMINATION
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